Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854329 | 1.00 | MAPK1 (0.43) | MAPK1SPRKDM4EL3MBTL1HPGDS | |
| SCHEMBL29801048 | 1.00 | MAPK1 (0.43) | MAPK1SPRKDM4EL3MBTL1HPGDS | |
| SCHEMBL29801107 | 0.87 | SPR (0.45) | MAPK1SPRKDM4EL3MBTL1HPGDS | |
| SCHEMBL24975414 | 0.87 | SPR (0.45) | MAPK1SPRKDM4EL3MBTL1HPGDS | |
| SCHEMBL29854306 | 0.87 | SPR (0.45) | MAPK1SPRKDM4EL3MBTL1HPGDS | |
| SCHEMBL4424437 | 0.83 | MAPK1 (0.50) | MAPK1KDM4EL3MBTL1HPGDSRXFP1 | |
| SCHEMBL24684991 | 0.82 | MAPT (0.40) | MAPK1SPRKDM4EL3MBTL1HPGDS | |
| SCHEMBL2617355 | 0.80 | PDK1 (0.53) | KDM4EL3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL24685404 | 0.80 | KDM4E (0.48) | MAPK1KDM4EL3MBTL1HPGDSRXFP1 | |
| SCHEMBL29801160 | 0.80 | KDM4E (0.48) | MAPK1KDM4EL3MBTL1HPGDSRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| CN-114929672-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, KIT, GLI1 | MAPK1 3430/4885SPR 3833/4885KDM4E 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.